ZYME Stock Recent News

The consensus price target hints at an 83.9% upside potential for Zymeworks (ZYME). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

Zymeworks Inc. (NASDAQ:ZYME ) Q1 2025 Earnings Conference Call May 8, 2025 4:30 PM ET Company Participants Shrinal Inamdar - Senior Director, Investor Relations Ken Galbraith - Chair & CEO Paul Moore - Chief Scientific Officer Leone Patterson - Executive Vice President, Chief Business and Financial Officer Conference Call Participants Charles Zhu - LifeSci Capital Brian Cheng - JPM Stephen Willey - Stifel Jonathan Miller - Evercore ISI Amanda Acosta-Ruiz - Leerink Partners Yigal Nochomovitz - Citigroup Eva Fortea-Verdejo - Wells Fargo Robert Burns - H.C. Wainwright Operator Thank you for standing by.

Zymeworks Inc. (ZYME) came out with a quarterly loss of $0.30 per share versus the Zacks Consensus Estimate of a loss of $0.45. This compares to loss of $0.42 per share a year ago.

VANCOUVER, British Columbia, May 08, 2025 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional biotherapeutics to improve the standard of care for difficult-to-treat diseases, including cancer, inflammation, and autoimmune disease, today reported financial results for the three months ended March 31, 2025 and provided a summary of recent business highlights.

Zymeworks is rated Strong Buy due to its improved outlook, FDA approval of Ziihera, advancing pipeline, and strong cash position. Zanidatamab (Ziihera) is a key asset with accelerated approval for HER2+ BTC and multiple ongoing trials in high-value indications. Despite past setbacks, Zymeworks' partnerships, potential milestones, and large target markets present significant upside potential for investors.

Zymeworks' FDA approval of Ziihera for HER2-positive biliary tract cancer validates its science, partnerships, and positions it for long-term value creation. Financial stability is evident with $76.3 million revenue in 2024 and a cash runway extending through late 2027. The robust pipeline includes zanidatamab for additional indications and promising early-stage candidates like ZW171 and ZW209 targeting high-unmet need cancers.

Six posters highlight continued progress across antibody-drug conjugate and T cell engager platforms Novel T cell engager ZW209 demonstrates durable activity in small cell lung cancer; IND submission expected in 1H-2026 VANCOUVER, British Columbia, April 25, 2025 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional biotherapeutics to improve the standard of care for difficult-to-treat diseases, including cancer, inflammation, and autoimmune disease, today announced the presentation of six posters with new preclinical data from its preclinical, development-stage, and clinical programs at the American Association for Cancer Research (AACR) Annual Meeting being held April 25-30, 2025 in Chicago, IL. “The breadth of data shared at AACR highlights the strength of our oncology portfolio across antibody-drug conjugates and T cell engagers, and demonstrates the novel approaches we employ using each m

VANCOUVER, British Columbia, April 21, 2025 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional biotherapeutics to improve the standard of care for difficult-to-treat diseases, including cancer, inflammation, and autoimmune disease, today announced that Sabeen Mekan, M.D., has been appointed as Senior Vice President, Clinical Development. Reporting directly to the Chief Executive Officer, Dr. Mekan will have a key role in formulating the clinical development strategy for Zymeworks' clinical-stage oncology portfolio, including global regulatory affairs. Dr. Jeff Smith, who joined Zymeworks in 2023, will continue as Executive Vice President & Chief Medical Officer, with primary responsibility for Zymeworks' emerging R&D portfolio in autoimmune and inflammatory disease and Global Clincal Development Operations. Ms. Barbara Schaeffler, who joined Zymeworks in 2024, has been promoted to Senior Vice

VANCOUVER, British Columbia, April 17, 2025 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional biotherapeutics to improve the standard of care for difficult-to-treat diseases, including cancer, inflammation, and autoimmune disease, today announced that management will report its first quarter 2025 financial results after market close on May 8, 2025. Following the announcement, management will host a conference call and webcast to discuss financial results and provide a corporate update on May 8, 2025 at 4:30 pm Eastern Time.

After a rough patch, it seems the biotech industry may be staging a comeback. Several biotech firms have gone public this year, and those focused on obesity treatments, gene therapies, and more have high expectations.